Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis
Authors:
- Silva Markovic-PleseSMSilva Markovic-Plese
- 1 September 2006
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 178 (1-2) , 130-139
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatinJournal of Experimental Medicine, 2006
- Blood–brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitisBrain, 2004
- Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through AtorvastatinJournal of Experimental Medicine, 2003
- 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathyProceedings of the National Academy of Sciences, 2002
- Pravastatin and the Development of Diabetes MellitusCirculation, 2001
- Transcriptional Analysis of Multiple Sclerosis Brain Lesions Reveals a Complex Pattern of Cytokine ExpressionThe Journal of Immunology, 2000
- Role of astrocytes in antigen presentation and naive T-cell activationJournal of Neuroimmunology, 2000
- Therapy of relapsing multiple sclerosis. Treatment approaches for nonrespondersJournal of Neuroimmunology, 1999
- HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Concentrations of Pravastatin and Lovastatin in Cerebrospinal Fluid in Healthy SubjectsClinical Neuropharmacology, 1991